Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 22

Showing 22 citing articles:

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 37
Molecular glue degraders: exciting opportunities for novel drug discovery
Thomas Lemaître, Marie Cornu, Florian Schwalen, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 433-449
Closed Access | Times Cited: 8
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 3, pp. 286-298
Closed Access
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
Zhaozhao Wang, S. Qu, Jiahao Yuan, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117514-117514
Closed Access | Times Cited: 9
mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
Xiaoqi Xue, Chen Zhang, Xiaolin Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 3
Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates
Yuying Shi, Gang Fan, Ruirong Tan, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 9
Open Access | Times Cited: 3
Recent progress in cancer immunotherapy: Application of nano-therapeutic systems
Robabehbeygom Ghafelehbashi, Mitra Salehi, Monireh Kouhi, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 91, pp. 105184-105184
Closed Access | Times Cited: 8
Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
Soumik De, Raghaba Sahu, Shubhendu Palei, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 112, pp. 117875-117875
Closed Access | Times Cited: 2
Shh–Gli2–Runx2 inhibits vascular calcification
Aoran Huang, Tianhua Xu, Xiaomei Lü, et al.
Nephrology Dialysis Transplantation (2023) Vol. 39, Iss. 2, pp. 305-316
Closed Access | Times Cited: 4
Construction and characterization of Fe 3 O 4 @BAAH-CuCl nanomagnetic catalyst: catalysis research in synthesis of 2-aryl quinazolines from prepared benzylamines
Khalid Mujasam Batoo, Mohammed Kadhem Abid, Ayadh Al-Khalidi, et al.
Journal of Coordination Chemistry (2024) Vol. 77, Iss. 5-6, pp. 448-465
Closed Access | Times Cited: 1
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
Construction of Pd Complex Immobilized on Magnetic Nanoparticles as an Efficient Nanocatalyst for Preparation of Diaryl Ketones
Ayman A. Ghfar, Xiaoliang Liu
Journal of Inorganic and Organometallic Polymers and Materials (2024)
Closed Access | Times Cited: 1
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 1
PROTAC<sup>®</sup> technology and potential for its application in infection control
M. A. Zakharova, М. В. Чудинов
Fine Chemical Technologies (2024) Vol. 19, Iss. 3, pp. 214-231
Open Access
Treating ICB-Resistant Cancer by Inhibiting PD-L1 via DHHC3 Degradation Induced by Cell Penetrating Peptide-Induced Chimera Conjugates
Miao Liu, Yuying Shi, Ruirong Tan, et al.
Research Square (Research Square) (2024)
Closed Access
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, et al.
Drug Delivery and Translational Research (2024)
Closed Access
Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
Wutong Zhao, Yongbin Jiang, Xiufen Li, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2024) Vol. 16, Iss. 6
Closed Access
Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs
Jie Huang, Xuekun Fu, Fang Qiu, et al.
Journal of the American Chemical Society (2024)
Closed Access
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Muhammad Zafar Irshad Khan, Adila Nazli, Iffat Naz, et al.
Journal of Pharmaceutical Analysis (2023)
Open Access | Times Cited: 1
Moving Beyond Amyloid in Alzheimer's Therapeutics
Anjali A. Sarkar
GEN Biotechnology (2023) Vol. 2, Iss. 2, pp. 69-75
Closed Access
Page 1

Scroll to top